Weekly Marketing Briefing: Cosentyx AI Monitoring

Week ending August 9, 2026

1. How AI is currently framing the brand

AI answers generally frame Cosentyx in a neutral, clinically explanatory way rather than as a clear winner. The dominant narrative is that Cosentyx is an IL-17A inhibitor with differences driven by mechanism, dosing, patient fit, and comorbidities—not broad superiority. However, answers are highly hedged: “shared decision-making,” “individual response varies,” and “talk to your clinician” recur frequently. Safety topics are prominent, with infection risk appearing 89 times across the dataset, while brand-level answers repeatedly qualify efficacy and comparative claims.

2. Share of voice vs. named competitors

Competitor mentions increased across the board as response volume rose from 60 to 140:

• Taltz: 17 mentions, up from 9
• Humira: 16, up from 7
• Stelara: 16, up from 7
• Enbrel: 15, up from 7
• Remicade: 6, up from 2
• Skyrizi: 3, up from 1
• Bimzelx: 1, down from 2

Taltz is the leading named competitor and appears in both the direct comparison question—“choosing Cosentyx versus Taltz”—and switching-related questions. Humira gains ground through plaque-psoriasis effectiveness and side-effect comparisons. Stelara is prominent in practical discussions of mechanism and dosing, while Enbrel is triggered by the recurring “is Cosentyx stronger?” question.

The risk is not overtly negative positioning: AI often says both products are legitimate options. The risk is that competitor names occupy valuable explanatory real estate inside Cosentyx answers.

3. Messaging consistency and content gaps

Several areas need authoritative, structured content that AI can retrieve consistently:

• Comparative decision content: Answers about Taltz, Humira, Stelara, and Enbrel repeatedly default to neutral trade-offs. Commission indication-specific comparison pages covering mechanism, dosing, evidence context, comorbidities, access, and tolerability—without superiority language.
• Dosing clarity: Answers consistently describe weekly loading followed by every-four-week maintenance, but timing varies (“starting at week 4,” “week 5,” or “week 8”). A clear, indication- and formulation-specific dosing hub with a visual schedule should reduce ambiguity.
• Switching and access: Switching answers identify prior authorization as “the biggest practical difference,” yet there is little brand-owned context to anchor that discussion. Build an SEO resource on switching, coverage, step therapy, onboarding, and what patients should ask their care team.
• Generic/biosimilar confusion: AI sometimes says Cosentyx is “commonly available as a biosimilar,” while other answers correctly distinguish a biologic from a traditional generic. Publish a precise substitution explainer, reviewed for current market and jurisdictional accuracy.
• Safety framing: IBD, infection, allergy, pregnancy, and monitoring details are inconsistently included. A prominently linked safety and patient-selection framework could improve completeness.

4. Overclaim / compliance-adjacent language watch

Reviewers should be aware that AI-generated answers currently circulate terms including “best,” “superior,” “stronger,” “most effective,” “strongest,” and “leading.” These appear 36 times overall, especially in comparisons with Taltz, Humira, and Enbrel. Some answers also describe Cosentyx as “more specific” or “targeted,” which may be interpreted as comparative positioning. This is language appearing in AI outputs—not language attributed to Cosentyx marketing.

A separate accuracy risk is the contradiction around boxed warnings: some answers incorrectly describe a boxed warning, while others state there is none. This warrants monitoring and corrective source content.

5. Recommended actions

1. Commission an indication-specific comparison hub, prioritizing Taltz, Humira, Stelara, and Enbrel, since they account for the most mentions.
2. Publish an authoritative dosing visual and FAQ, addressing the week-4/week-5/week-8 inconsistencies.
3. Create a switching and access guide, directly targeting the repeated prior-authorization narrative.
4. Build a generic-versus-biosimilar/substitution explainer with current regulatory and pharmacy caveats.
5. Strengthen safety source pages, especially infection, IBD, pregnancy, vaccination, and boxed-warning language, with medical-legal review.